Background Nuclear factor erythroid-2 related factor 2 (NRF2) is a redox-sensitive transcription
factor that positively regulates the expression of genes encoding antioxidants, xenobiotic …

Small-cell lung cancer (SCLC) is an exceptionally aggressive disease with poor prognosis.
Here, we obtained exome, transcriptome and copy-number alteration data from …

Background Ever since a lung cancer epidemic emerged in the mid-1900s, the epidemiology
of lung cancer has been intensively investigated to characterize its causes and patterns of …

Immune checkpoint inhibitors have shown significant therapeutic responses against tumors
containing increased mutation-associated neoantigen load. We have examined the evolving …

Epigenetic alterations are strongly associated with the development of cancer. We conducted
a phase I/II trial of combined epigenetic therapy with azacitidine and entinostat, inhibitors …

Background Despite optimal and early surgical treatment of non–small-cell lung cancer (NSCLC),
many patients die of recurrent NSCLC. We investigated the association between gene …

Reversal of promoter DNA hypermethylation and associated gene silencing is an attractive
cancer therapy approach. The DNA methylation inhibitors decitabine and azacitidine are …

PD-1 blockade unleashes CD8 T cells 1 , including those specific for mutation-associated
neoantigens (MANA), but factors in the tumour microenvironment can inhibit these T cell …

In the United States, the 20th century witnessed the emergence of a lung cancer epidemic
that peaked and began to decline by the century's end, a decline that continues today. …

Innovative therapies are needed for advanced Non-Small Cell Lung Cancer (NSCLC). We
have undertaken a genomics based, hypothesis driving, approach to query an emerging …